We assessed a homogenous KRAS mutation status between several pre- and post-therapeutic tissue samples of the primary tumor indicating no relevant intratumoral heterogeneity and concluded, that discordance is a very rare event [12]. The gene discussed is KRAS; the disease is neoplasm.